Holen Sie sich die Stockscreener-App
81.49
0.54%
-0.44
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics (PTGX) to Release Earnings on Friday - MarketBeat
Does Protagonist Therapeutics Inc. stock trade at a discount to peersJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - mfd.ru
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy - Finviz
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Protagonist Therapeutics director sells $1.67 million in shares By Investing.com - Investing.com Canada
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 20,000 Shares of Stock - MarketBeat
Assessing Protagonist Therapeutics (PTGX) Valuation After Rusfertide NDA Filing And Rising Analyst Optimism - simplywall.st
Precision Trading with Protagonist Therapeutics Inc. (PTGX) Risk Zones - Stock Traders Daily
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - El Paso Times
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech Gem with 22% Upside Potential - DirectorsTalk Interviews
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - The Asheville Citizen Times
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $118.00 at Jefferies Financial Group - MarketBeat
Jefferies Raises Price Target for PTGX to $118, Maintains 'Buy' Rating | PTGX Stock News - GuruFocus
ClearBridge small-cap growth trims Duolingo, Biohaven, QLYS; adds PTGX, SSD, BETA, DYN in Q4 - MSN
Equities Analysts Set Expectations for PTGX FY2030 Earnings - MarketBeat
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes - AOL.com
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
PTGX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | PTGX Stock News - GuruFocus
Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views - Benzinga
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright - Investing.com Canada
Protagonist Therapeutics CMO Sells Shares in Major Transaction - Intellectia AI
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Great Lakes Advisors LLC - MarketBeat
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide - Seeking Alpha
Protagonist Therapeutics CEO Patel sells $4m in shares By Investing.com - Investing.com South Africa
Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock - Investing.com Canada
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Protagonist Therapeutics CEO Patel sells $4m in shares - Investing.com
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 5,000 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 13,151 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 24,890 Shares of Stock - MarketBeat
Protagonist Therapeutics chief medical officer sells $1.9m in shares By Investing.com - Investing.com Canada
JPMorgan reiterates Overweight rating on Protagonist Therapeutics stock By Investing.com - Investing.com Canada
VIX Spike: Can Protagonist Therapeutics Inc weather a recessionStop Loss & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Technical Reactions to PTGX Trends in Macro Strategies - Stock Traders Daily
Have Insiders Sold Protagonist Therapeutics Shares Recently? - Sahm
Earnings Risk: Will Protagonist Therapeutics Inc benefit from AI trendsAnalyst Downgrade & Daily Market Momentum Tracking - baoquankhu1.vn
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - citizen-times.com
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com - Investing.com India
Protagonist therapeutics CMO Molina sells $784k in shares By Investing.com - Investing.com Canada
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock - MarketBeat
Protagonist therapeutics CEO Patel sells $2.84 million in shares - Investing.com
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings Signal Potential 17% Upside - DirectorsTalk Interviews
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):